Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.
Timothy A HowellLouis S MatzaMonika P JunJacob GarciaAnnette PowersDavid G MaloneyPublished in: PharmacoEconomics - open (2022)
More severe AEs were associated with greater disutilities. Health state utilities estimated in this study may be useful in cost-effectiveness models examining the value of CAR T-cell therapy in patients with LBCL.